What is LIMN's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for LIMN.

Stock Ratings / Health Care / LIMN / options

CRIS (27) PMCB (34) BTTC (38) CELZ (20) ⌘ Pro Terminal →

Liminatus Pharma Inc. (Class A) (LIMN) Options Positioning, Max Pain & Unusual Sweeps

$2.52 -10.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.47

Liminatus Pharma Inc. (Class A) (LIMN) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $3.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LIMN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LIMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Liminatus Pharma Inc. (Class A) (NASDAQ: LIMN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.52 (-10.64% 1D, market cap $3.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LIMN ranks #613 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LIMN compare to CRIS and PMCB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LIMN carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRIS (Curis Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M) and PMCB (PharmaCyte Biotech Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -30.2%, cap $3.2M). Among the 5-stock peer group, LIMN leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LIMN?

▼

Per LIMN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971387), Liminatus Pharma Inc. (Class A) generated $8.3M in revenue (-10.9% YoY), -$10.2M in net income, and -$10.0M in free cash flow against $512.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.47 (-2.11%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LIMN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY LIMN SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 35.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.41-5.6% Next Q

Q2 (-2Q)

Grade D$3.22-10.2% Next Q

Q3 (-1Q)

Grade E$2.89-12.8% Next Q

Current

Grade D-$2.52-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LIMN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LIMN currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.58) and Max Pain ($2.65) forces dealer call-delta covering toward $148.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LIMN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LIMN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (LIMN)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for LIMN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LIMN)

✓Walkthrough of LIMN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LIMN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -76.34%🛡️ HOLDING TREND SUPPORT

2026-11-03O $2.89H $2.89L $2.52C $2.52VOL 13.0K

RES: $6.94SUP: $2.10SMA50: $3.58SMA200: $10.74

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LIMN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LIMN Butterfly Map → + Track LIMN →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LIMN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LIMN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LIMN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LIMN)

Health Care Rank #613 of 1016 ⚔️ CRIS vs LIMN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LIMN vs. CRIS, PMCB, BTTC, CELZ)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Liminatus Pharma Inc. (Class A) (LIMN) ranks #613 by composite RQD confidence (35/100, grade D-) and #960 by equity capitalization ($3.8M). Within this direct 5-issuer industry benchmark cohort, LIMN leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with LIMN at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LIMN ACTIVE Liminatus Pharma Inc. (Class A)	D-	35/100	—	—	-35.0%	-10.64%	$3.8M	Benchmark Subject
CRIS Curis Inc.	E	27/100	—	—	-35.0%	+10.17%	$4.0M	/cris-vs-limn →
PMCB PharmaCyte Biotech Inc.	E	34/100	—	—	-30.2%	+2.71%	$3.2M	/pmcb-vs-limn →
BTTC Black Titan Corporation	D-	38/100	—	—	—	-3.17%	$4.8M	/bttc-vs-limn →
CELZ Creative Medical Technology Holdings Inc.	E	20/100	—	63.4%	-35.0%	-4.81%	$5.0M	/celz-vs-limn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001971387

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Liminatus Pharma Inc. (Class A) (LIMN) reported GAAP revenue of $8.3M (-10.9% vs. FY2024 revenue of $9.3M ) , GAAP net income of -$10.2M, operating cash flow of -$10.0M, and free cash flow of -$10.0M (-587.5% YoY). On the balance sheet, LIMN closed FY2025 with $512.8K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$8.3M	-$10.2M	-$10.0M	-$10.0M	$512.8K	—
FY2024 (FY)	2024-12-31	$9.3M	-$3.5M	-$1.5M	-$1.5M	$5.4M	—

3. LIMN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LIMN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LIMN compare to CRIS and PMCB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LIMN?

Where is LIMN trading relative to its 50-day, 200-day, and 52-week technical levels?

LIMN last traded at $2.52 (-10.64% on volume of 23,977 shares), positioning the stock -29.61% below its 50-day simple moving average ($3.58) and -76.54% below its 200-day simple moving average ($10.74). Across its 52-week range of $2.75 to $141.50, LIMN sits at the 0.0% percentile with a 14-day RSI of 35.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.20 to $2.84).

Direct Sub-Reports: LIMN RQD Cockpit LIMN 12M Forecast LIMN Earnings & Move LIMN Dividends & DRIP LIMN Insiders & 13F LIMN Whale Options LIMN Profit Sankey LIMN News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

LIMN — Liminatus Pharma Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Liminatus Pharma Inc. (Class A) (LIMN) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.52 (-10.64% 1D, market capitalization $3.8M).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Liminatus Pharma Inc. (Class A) (LIMN) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..0B. —: specific products, customers, or revenue model descriptions.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Liminatus Pharma Inc. (Class A) (LIMN) reported $8.3M in annual revenue (up from $9.3M in FY2024, -10.9% YoY) and -$10.2M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($9.3M revenue, -$3.5M net income) through FY2025, LIMN scaled operating cash flow to -$10.0M and free cash flow to -$10.0M, backed by $512.8K in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.75 – $141.50 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

—: upstream suppliers, downstream customers, and sector correlation mappings. Investors should note that the 52-week range and the presence of a warrant-related reference (LIMNW) in the news feed are the only ripple-type observations available, and neither is resolved by the source data.

Key Question #1: Can LIMN sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $8.3M and free cash flow of -$10.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is LIMN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LIMN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Liminatus Pharma Inc. (Class A) (LIMN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LIMN Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 20h ago

Liminatus Pharma, Inc. Estimates – NASDAQ:LIMN

TradingView report covering Liminatus Pharma Inc. (Class A) (LIMN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 23h ago

aTyr Pharma, Inc. (ATYR) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Liminatus Pharma Inc. (Class A) (LIMN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Australia • 1d ago

CDT Equity Inc. (CDT) stock price, news, quote and history

Yahoo Finance Australia report covering Liminatus Pharma Inc. (Class A) (LIMN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Liminatus (LIMNW) Stuck at $0.04 — Which Way Will It Break? 2026-10-30 - Dividend Arbitrage

https://www.siam.in/ report covering Liminatus Pharma Inc. (Class A) (LIMN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Australia • 1d ago

Adlai Nortye Group Ltd. (ANL) stock price, news, quote and history

Yahoo Finance Australia report covering Liminatus Pharma Inc. (Class A) (LIMN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Tenaya Therapeutics, Inc. (TNYA) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Liminatus Pharma Inc. (Class A) (LIMN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

CDT Equity Inc. (CDT) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Liminatus Pharma Inc. (Class A) (LIMN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LIMN Bull vs. Bear Conversation Board — What's Your Call at $2.52?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LIMN 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $3.61 (+28.0%)

📌 Pinned Debate

The stock trades at a $3.9M market capitalization, so a meaningful shift in cash generation or sponsorship could move the valuation sha

Picked up a starter position in LIMN in my $100K Virtual Cash book at $2.82. The stock trades at a $3.9M market capitalization, so a meaningful shift in cash generation or sponsorship could move the valuation sharply from its current low base.. Trading inside a $2.75–$141.50 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@TapeReader_Pro Agree on the RQD 35/100 quality, though with 1.0 beta I'm scaling in with half-size at $2.82 and keeping dry powder in case we test $2.62.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $2.37 (-16.0%)

Spot @ $2.82

With ROIC at -35%, FCF yield at 0%, Piotroski F at 1/9, and a 52-week range of $2.75 to $141.5, the data points to ongoing losses and w

Careful chasing LIMN at $2.82. With ROIC at -35%, FCF yield at 0%, Piotroski F at 1/9, and a 52-week range of $2.75 to $141.5, the data points to ongoing losses and weak forensic quality.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $2.37 on multiple compression.